SCHEMBL23306166

SCHEMBL23306166

CC(C)(C)OC(=O)N1CC2(C1)CN(c1ccc(Br)nc1)C2

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 1/20 0.46
GPR119 Q8TDV5 8/20 0.45
RET P07949 3/20 0.42
CYP11B2 P19099 1/20 0.42
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39
WNT3A P56704 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
NR1H2 P55055 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29840476 1.00 EGLN2 (0.46) EGLN2GPR119RETCYP11B2MAPT
SCHEMBL13015255 0.86 MAPT (0.47) EGLN2GPR119RETCYP11B2MAPT
SCHEMBL31590440 0.85 EGLN2 (0.46) EGLN2GPR119RETCYP11B2MAPT
SCHEMBL30484801 0.85 EGLN2 (0.46) EGLN2GPR119RETCYP11B2MAPT
SCHEMBL13015535 0.85 EGLN2 (0.46) EGLN2GPR119RETCYP11B2MAPT
SCHEMBL611746 0.85 EGLN2 (0.46) EGLN2GPR119RETCYP11B2MAPT
SCHEMBL594965 0.84 MAPT (0.56) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL30150192 0.84 MAPT (0.56) GPR119MAPTMEN1TSHRKMT2A
SCHEMBL21877081 0.83 RORC (0.47) EGLN2GPR119CYP11B2MAPTSMN1; SMN2
SCHEMBL31464333 0.83 GPR183 (0.47) EGLN2GPR119RETCYP11B2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117470-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS SYNGENE INTERNATIONAL LIMITED (IN) 2023-04-20 US disclosed
WO-2021087181-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117470-A1 SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS TLR1, TLR3, TLR9 EGLN2 3651/4885GPR119 77/4885RET 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.